‘I just hate being away from my family’

Motley Fool

Here’s Why Exact Sciences Jumped 21.5% in October

Shares of Exact Sciences (NASDAQ: EXAS) jumped 21.5% in November, according to data from S&P Global Market Intelligence, after the diagnostic testing company posted solid third-quarter results and announced an acquisition that could help drive growth in the years to come. The year-over-year comparison was also boosted by the addition of $91.6 million in sales of precision oncology tests that Exact Sciences got in the acquisition of Genomic Health, which closed last November. Screening revenue, which includes sales of Exact’s legacy colon cancer test, Cologuard, and revenue from Biomatrica products, fell 2% year over year.

Source link

Add a Comment